Lifesci Capital Issues Optimistic Outlook for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at Lifesci Capital increased their Q2 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Tuesday, March 24th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings of ($0.01) per share for the quarter, up from their previous estimate of ($0.36). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ FY2026 earnings at ($0.66) EPS.

A number of other brokerages have also recently weighed in on TARS. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. The Goldman Sachs Group restated a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.83.

Tarsus Pharmaceuticals Stock Down 1.4%

Shares of TARS opened at $66.25 on Thursday. The stock has a market capitalization of $2.82 billion, a PE ratio of -40.89 and a beta of 0.55. Tarsus Pharmaceuticals has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The company’s 50-day simple moving average is $68.24 and its 200-day simple moving average is $70.49.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 4,174 shares of the firm’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $279,658.00. Following the sale, the insider directly owned 35,028 shares in the company, valued at $2,346,876. This trade represents a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 4,231 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $283,477.00. Following the transaction, the general counsel directly owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. This represents a 6.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 79,391 shares of company stock worth $5,432,035. 8.97% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. RTW Investments LP raised its holdings in Tarsus Pharmaceuticals by 5.0% during the fourth quarter. RTW Investments LP now owns 3,335,320 shares of the company’s stock worth $273,096,000 after purchasing an additional 157,884 shares in the last quarter. Deep Track Capital LP boosted its holdings in shares of Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $178,290,000 after buying an additional 1,250,000 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after buying an additional 136,582 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Tarsus Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after buying an additional 127,470 shares during the last quarter. Finally, Morgan Stanley grew its position in shares of Tarsus Pharmaceuticals by 6.7% in the 4th quarter. Morgan Stanley now owns 2,040,742 shares of the company’s stock valued at $167,096,000 after buying an additional 128,340 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.